Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry

• Verfasst von: Suzuki, Yosuke [VerfasserIn]
• Verfasst von: Witt, Lukas [VerfasserIn]
• Verfasst von: Mier, Walter [VerfasserIn]
• Verfasst von: Mikus, Gerd [VerfasserIn]
• Verfasst von: Markert, Christoph [VerfasserIn]
• Verfasst von: Haefeli, Walter E. [VerfasserIn]
• Verfasst von: Burhenne, Jürgen [VerfasserIn]
• Titel: Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry
• Verf.angabe: Yosuke Suzuki, Lukas Witt, Walter Mier, Gerd Mikus, Christoph Markert, Walter E. Haefeli, Jürgen Burhenne
• Umfang: 7 S.
• Fussnoten: Available online 29 April 2017 ; Gesehen am 20.06.2018
• Titel Quelle: Enthalten in: Journal of pharmaceutical and biomedical analysis
• Jahr Quelle: 2017
• Band/Heft Quelle: 142(2017), S. 84-90
• ISSN Quelle: 1873-264X
• DOI: doi:10.1016/j.jpba.2017.04.038
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1576580636

Abstract

Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor peptide and the plasma concentrations are commonly quantified by immunoassays such as enzyme-linked immuno-sorbent assays (ELISA) with the disadvantage of possible cross-reactivity with closely related endothelin derivatives. The aim of this study was to develop and validate an ultra-sensitive and selective assay for the quantification of ET-1 in human plasma, using ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) after solid phase extraction. The assay fulfilled the requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) guidelines for assay validation, with a lower limit of quantification of 1.5pg/mL for ET-1. Recovery rates from plasma ranged between 80.8% and 93.6%, and matrix effect varied between 121% and 135%. The assay was successfully applied to assess the time course of plasma ET-1 concentrations in two human volunteers after co-administration of bosentan and clarithromycin. In this trial, the concentrations measured by UPLC-MS/MS were slightly lower than those measured by ELISA, with a strong positive correlation between the two methods. Our novel UPLC-MS/MS method is applicable to the clinical setting and may have better selectivity for ET-1 than ELISA.